Background {#Sec1}
==========

Gastrointestinal (GI) fistula is a complex and challenging problem associated with intra-abdominal infections (IAIs), leading to high morbidity and mortality worldwide \[[@CR1], [@CR2]\]. Effective treatment for IAIs patients involves both source control and antimicrobial therapy \[[@CR3]\]. Despite improvements in patient care, therapeutic failure remains common \[[@CR4]\].

Selection and prompt initiation of the appropriate empiric antimicrobial therapy play an important role in decreasing morbidity and mortality in GI fistula patients with IAIs \[[@CR5]\]. The Infectious Diseases Society of America (IDSA) guidelines recommend use of single agents, such as carbapenems, piperacillin/tazobactam, cephalosporins, fluoroquinolones and aminoglycosides combined with metronidazole to treat IAIs in adults \[[@CR2]\]. The distribution of pathogens causing IAIs and their drug susceptibility profiles may change over time, particularly with the spread of antibiotic resistance, making it more challenging for surgeons to select appropriate antibiotic therapies \[[@CR6], [@CR7]\]. To improve the outcome of GI fistula patients with IAIs, it is essential for surgeons to be aware of the local bacteriology and antimicrobial resistance trends of the causative pathogens \[[@CR8]\].

Large-scale antibiotic susceptibility surveillances have been launched over the past decades which have informed surgeons of current trends in the emergence of antibiotic-resistant bacterial strains involved in IAIs \[[@CR9]--[@CR11]\]. However, these short-term surveillances might put up an incomplete facade pattern as the fluctuations of antibiotic resistance appeared in the shorter time period \[[@CR12]\]. Therefore, a longitudinal surveillance is critical as guidance for empiric therapy.

Methods {#Sec2}
=======

Patients and samples {#Sec3}
--------------------

Microbiology and antibiotic susceptibility of isolates collected at Jinling Hospital between 2008 and 2015 were retrospectively reviewed using the hospital medical record system. Data extracted from the system for each isolate included demographic characteristics of the patient (age, sex), co-morbidities (hypertension, diabetes, cancer, inflammatory bowel disease, lung injury, renal injury) and fistula location. Upper GI fistula was defined as fistula located in the stomach or duodenum and lower GI fistula was defined as fistula located in the jejunum, ileum or colon \[[@CR13]\]. Isolates from tissue, fluid or deep wound cultures obtained during operation, abdominal drains, fluid from paracentesis or percutaneous aspiration of abscesses were included, and those from drain bottles, stool, superficial wounds, or perirectal abscess were excluded.

The study protocol was approved by the Institutional Review Board Ethics Committee of Jinling Hospital, and all research work was in compliance with the Helsinki Declaration.

Pathogenic examination and antibiotic susceptibility determination {#Sec4}
------------------------------------------------------------------

Samples were collected with sterile cotton swabs (Zhejiang Gongdong Medical Technology Co. Ltd., Taizhou, Zhejiang, China) and then sent to the microbiology laboratory for processing. Bacteria were isolated and then identified by the Vitek and Analytical Profile Index (API) bacterial identification systems or by traditional manual methods (BioMérieux, Hazelwood, MO, USA).

To assess antimicrobial susceptibility, minimum inhibitory concentrations (MICs) for each antimicrobial agent were determined by the agar dilution method, according to each year's CLSI guidelines (Clinical Laboratory Standards Institute, USA, as annually updated) \[[@CR14]\]. Phenotypic identification of extended-spectrum beta-lactamase (ESBL) production of *Escherichia. Coli* (*E. coli)*, *Klebsiella* and *Enterobacter species* were expanded. If MICs of ceftazidime, cefepime, or ceftriaxone were ≥2 mg/L among *E. coli, Klebsiella* or *Enterobacter species*, ESBL production was suspected. For these ESBL-suspected isolates, if the MIC of cefepime was at least eightfold more than that of cefepime in the presence of clavulanic acid, ESBL production was identified \[[@CR15]\]. *Escherichia coli* ATCC 25922, *Klebsiella pneumonia* ATCC 700603 and *Pseudomonas aeruginosa* ATCC 27853 were used as quality control strains.

Statistical analysis {#Sec5}
--------------------

Descriptive statistics were presented for categorical variables and continuous variables. We divided the study period into two periods for analysis: 2008--2011 and 2012--2015. We use the Mantel--Haenszel linear-by-linear association χ^2^ test to detect significant differences over time. Continuous variables were analyzed using the student t-test. *P* \< 0.05 was considered statistically significant. All statistical analyses were performed using SPSS software (Version 22 IBM, Armonk, NY).

Results {#Sec6}
=======

Patient characteristics {#Sec7}
-----------------------

A total of 502 GI fistula patients (mean age 46.5 years, 71.1% male) were included. Demographic characteristics of included patients are shown in Table1. Patients in the second study period (2012--2015) exhibited significant enrichment of clinical factors, including advanced age (*P* = 0.02), cancer (16.0% VS 6.7%, *P* = 0.001) and renal injury (16.7% VS 9.2%, *P* = 0.013) than patients from 2008 to 2011. In addition, the 2012--1015 cohort had a significantly higher percentage of lower GI fistula (*P* = 0.005) and a lower percentage of intensive care unit (ICU) patients (*P* \< 0.001) (Table [1](#Tab1){ref-type="table"}). We did not find the difference change in mortality rates over time (27.6% VS 28.1%, *P* = 0.896).Table 1Clinical characteristics of patients during 2008 and 20152008--2012\
(*n* = 239)2012--2015\
(*n* = 263)*P*Gender Male169 (70.71%)188 (71.48%)0.849Age (years)44.85 ± 14.9948.05 ± 15.620.020  ≤ 166 (2.51%)3 (1.14%)0.248 17--3249 (20.50%)41 (15.59%)0.152 33--4888 (36.82%)96 (36.50%)0.941 49--6476 (31.80%)81 (30.80%)0.809  ≥ 6520 (8.37%)42 (15.97%)0.010Patient location ICU150 (62.76%)123 (46.77%)\<0.001Fistula location, Upper gastrointestinal107 (45.15%)98 (37.26%)0.073 Lower gastrointestinal106 (44.35%)150 (57.03%)0.005 Both19 (7.95%)15 (5.70%)0.317Co-morbidities Hypertension39 (16.32%)57 (21.67%)0.128 Diabetes20 (8.37%)30 (11.41%)0.256 Cancer16 (6.69%)42 (15.97%)0.001 IBD8 (3.35%)16 (6.08%)0.151 Lung Injury33 (13.81%)45 (17.11%)0.308 Renal Injury22 (9.21%)44 (16.73%)0.01330-day mortality66 (27.62%)74 (28.14%)0.896

Microbiological profile {#Sec8}
-----------------------

During the entire study period, 874 isolates were collected, and the mean number of isolates per year was 109+/−19. Co-infection with multiple microbial strains was identified in 118(49.4%) patients during the first study period and 124(47.2%) during the second period. The distribution of microbial strains, stratified by study period, is shown in Fig. [1](#Fig1){ref-type="fig"}. The total number of Gram-negative was 638 (73.0%), which became more common over time (*P* = 0.024), followed by Gram-positive isolates (188, 25.5%), respectively. Overall, *E. coli* was the most frequently identified bacterial microorganism (216 isolates, 24.2% of all bacterial growths and 33.9% of Gram-negative isolates), followed by *K. pneumonia* (123 isolates, 14.1% of all bacterial growths and 19.3% of Gram-negative isolates). A significant decrease in the percentage of *E. coli* isolates that were ESBL-positive occurred between study periods (*P* = 0.026), but there was no significant difference in the proportion of *K. pneumonia* that were ESBL positive between study periods. The common Gram-positive bacteria were *Enterococcus* and *Staphylococcus*. (Additional file [1](#MOESM1){ref-type="media"}: Table S1).Fig. 1Distribution of strain groups identified in the study periods

*Enterobacteriaceae* antibiotic resistance {#Sec9}
------------------------------------------

Tables [2](#Tab2){ref-type="table"} and [3](#Tab3){ref-type="table"} list the in vitro resistance profiles of *E. coli* and *K. pneumonia,* respectively, stratified by ESBL-production ability. There were similar patterns of antibiotic resistance for *E. coli* and *K. pneumonia* isolates over the study period, with both displaying high levels of resistance to penicillins, cephalosporins and fluoroquinolones. There was a statistically significant decrease in prevalence of resistance to ceftazidime and cefepime in *E. coli* isolates (*P* = 0.042, *P* = 0.035). No significant change in prevalence of resistance to aztreonam and amikacin was observed in both *E. coli* and *K. pneumonia* isolates. Resistance to amikacin was relatively low compared with the other antibiotics mentioned above for both *E. coli* and *K. pneumonia* isolates.Table 2Antimicrobial resistance of *Escherichia coli* isolates to the tested antibioticsResistance rate (%)Isolate/Antibiotics2008--20112012--2015TotalP for Trend TestAll *Escherichia coli* AMK7.7814.1611.330.154 AMP97.9296.4997.140.537 SAM81.9787.9385.880.279 TZP23.4725.0024.300.795 CZO92.5591.3091.870.742 CAZ81.8269.8375.35**0.042** FEP75.5162.0768.22**0.035** IPM14.2925.8620.56**0.037** CIP90.1679.1382.950.064ESBL+ AMK6.7812.339.850.287 AMP100.00100.00100.00-- SAM77.7893.1588.07**0.020** TZP20.316.8513.14**0.020** SXT84.2173.6177.270.207 CZO100.00100.00100.00-- CAZ89.2368.4978.26**0.003** FEP81.2560.2770.07**0.007** IPM12.318.2210.140.427 CIP86.1180.8282.570.494ESBL- AMK6.6716.2213.460.361 AMP88.2489.7489.290.867 SAM77.7877.5077.550.986 ZP35.2957.5050.880.125 SXT88.8967.5071.430.199 CZO58.8274.3669.640.245 CTT28.5770.0063.83**0.035** CAZ52.9470.0064.910.217 FEP52.9462.5059.650.501 IPM43.7557.5053.570.351 CIP88.8977.5079.590.444Not all tested antibiotics are listed*AMK* Amikacin, *AMP* Ampicillin, *SAM* Ampicillin/Sulbactam, *CAZ* Ceftazidime, efepime, *CTT* Cefotetan, *CZO* Cefazolin, *IPM* Imipenem, *TZP* Piperacillin-Tazobactam, *CIP* CiprofloxacinData in boldface reflected p values \< 0.05 Table 3Antimicrobial resistance of *Klebsiella pneumonia* isolates to the tested antibioticsResistance rate (%)Isolate/Antibiotics2008--20112012--2015TotalP for Trend TestAll *Klebsiella pneumonia* AMK40.9136.1137.930.605 SAM97.1485.1488.990.061 TZP75.0058.1164.750.056 CTT60.6154.7956.600.576 CAZ89.8078.3882.930.099 FEP75.0067.5770.490.379 IPM65.3156.7660.160.343 CIP74.2975.6875.230.875ESBL+ AMK33.337.4116.67**0.031** SAM100.0089.2992.110.281 TZP55.5617.8632.61**0.008** CTT12.5014.8114.290.869 CAZ94.4471.4380.430.055 FEP83.3353.5765.22**0.039** IPM38.8914.2923.910.056 CIP50.0071.4365.790.220ESBL- AMK40.9153.3349.250.339 SAM94.4482.6185.940.221 TZP86.3682.6183.820.694 CTT88.8978.2681.250.327 CAZ82.6182.6182.61-- FEP72.7376.0975.000.765 PM78.2682.6181.160.663 CIP83.3378.2679.690.650Not all tested antibiotics are listed*AMK* Amikacin, *SAM* Ampicillin/Sulbactam, *CAZ* Ceftazidime, *FEP* Cefepime, *CTT* Cefotetan, *IPM* Imipenem, *TZP* Piperacillin-Tazobactam, *CIP* CiprofloxacinData in boldface reflected p values \< 0.05

In ESBL-positive *E. coli*, prevalence of resistance to piperacillin/tazobactam (13.1%) was lower than ampicillin/sulbactam resistance prevalence (88.1%) and both decreased over the study period (*P* = 0.020). The same resistance trend to piperacillin/tazobactam was also observed in ESBL-positive *K. pneumonia* (*P* = 0.008). Imipenem resistance prevalence was higher in *K. pneumonia* than *E. coli.* It increased over time in *E. coli* (14.3% VS 25.9%, *P* = 0.037) but there was no significant change in *K. pneumonia* (65.3% VS 56.8%, *P* = 0.343). Imipenem resistance prevalence was higher in ESBL-negative than ESBL-positive bacteria for both *E. coli* and *K. pneumonia* (*P* \< 0.001).

Antimicrobial resistance of non-fermenting bacteria {#Sec10}
---------------------------------------------------

In *A. baumannii* isolates, extremely high levels of cephalosporin resistance were observed, which increased to 100% in 2012--2015. In contrast, ceftazidime and cefepime resistance rates were lower in *P. aeruginosa* isolates (Table [4](#Tab4){ref-type="table"}). Both *A. baumannii* and *P. aeruginosa* showed strikingly high resistance rates to imipenem during the study period. Among *A. baumannii* isolates*,* imipenem resistance prevalence was 95.6% and did not significantly change during the study period. In contrast, imipenem resistance in *P. aeruginosa* isolates was much lower. Resistance to fluoroquinolones showed no significant change over time in either pathogen.Table 4Antimicrobial resistance of *Acinetobacter baumannii* and *Pseudomonas aeruginosa* isolates to the tested antibioticsResistance rate (%)Isolate/Antibiotics2008--20112012--2015TotalP for Trend TestAcinetobacter baumannii AMP96.43100.0098.550.223 SAM90.48100.0096.77**0.045** TZP96.3095.0095.520.801 SXT95.2473.1780.65**0.037** CRO94.44100.0098.310.128 CTX100.00100.00100.00-- CAZ88.89100.0095.59**0.029** FEP96.30100.0098.530.214 IPM96.3095.1295.590.818 LVX66.6756.1060.290.383 CIP95.2497.5696.770.624Pseudomonas aeruginosa AMK31.8222.2225.860.418 SAM100.00100.00100.00-- TZP60.8733.3344.07**0.038** ATM58.8275.0061.900.549 SXT100.0097.2298.110.488 CRO100.00100.00100.00-- CTX100.00100.00100.00-- CAZ69.5761.1164.410.508 FEP65.2250.0055.930.251 IPM73.9158.3364.410.223 LVX34.7844.4440.680.461 CIP38.8941.1840.380.873Not all tested antibiotics are listed*AMK* Amikacin, *SAM* Ampicillin/Sulbactam, *TZP* piperacillin-tazobactam, *ATM* Aztreonam, *SXT* Trimethoprim/Sulfamethoxazole, *CRO* Ceftriaxone, *CTX* cefotaxime, *CAZ* ceftazidime, *FEP* cefepime, *IPM* imipenem, *LVX* levofloxacin, *CIP* ciprofloxacinData in boldface reflected p values \< 0.05

Antimicrobial resistance of gram-positive bacteria and fungi {#Sec11}
------------------------------------------------------------

Antibiotic resistance prevalence rates of Gram-positive bacteria are listed in Table [5](#Tab5){ref-type="table"}. In *Enterococcus*, resistance to ampicillin increased from 72.2% in 2008--2011 to 92.5% in 2012--2015 (*P* = 0.01). Resistance to moxifloxacin also increased significantly (*P* = 0.02). No significant changes in resistance to vancomycin (*P* = 0.311) and linezolid (*P* = 0.111) over time were observed.Table 5Antimicrobial resistance of *Enterococcus* and *Staphylococcus* isolates to the tested antibioticsResistance rate (%)Isolate/Antibiotics2008--20112012--2015TotalP for Trend TestEnterococcus AMP72.2292.4584.27**0.01** STH47.0657.5852.240.389 GEH71.7479.2575.760.385 ERY88.5788.6888.640.988 CIP89.2990.5790.120.854 CLI100.0095.5695.920.667 MFX63.6491.1185.71**0.02** PEN87.2392.3189.900.403 TCY74.2969.2371.260.609 VAN4.269.437.000.311 LNZ4.880.002.170.111 LVX77.1490.3885.060.089Staphylococcus OXA82.6993.1086.420.190 SXT47.6224.1438.030.045 ERY84.6282.7683.950.827 CIP73.6889.6683.330.147 CLI69.5757.1464.860.278 MFX46.3437.9342.860.484 PEN94.34100.0096.340.192 GEN71.1572.4171.600.904 TCY56.8268.9761.640.296 VAN0.000.000.00-- LNZ0.000.000.00-- LVX68.8979.3172.970.324Not all tested antibiotics are listed*AMP* Ampicillin, *OXA* Oxacillin, *STH* Streptomycin-High, *SXT* Trimethoprim/Sulfamethoxazole, *ERY* erythromycin, *GEH* gentamicin, *CIP* ciprofloxacin, *CLI* Clindamycin, *MFX* moxifloxacin, *PEN* penicillin, *TCY* tetracycline, *VAN* Vancomycin, *LNZ* Linezolid, *LVX* LevofloxacinData in boldface reflected p values \< 0.05

Methicillin-resistant *S. aureus* (MRSA) accounted for 94.1% of *S. aureus* isolates in 2012--2015. There was no significant change in *S. aureus* resistance to oxacillin over time. All of 51 *Staphylococcus* were susceptible to vancomycin (Table [5](#Tab5){ref-type="table"}).

Fungi isolates showed lower antibiotic resistance rates than bacteria isolates, and rates did not significantly vary over time (Table [6](#Tab6){ref-type="table"}).Table 6Antimicrobial resistance of *Fungi* isolates to the tested antibioticsResistance rate (%)Antibiotics2008--20112012--2015TotalP for Trend Test FLU18.188.3311.430.395 VOR0.008.335.710.324 ITR18.185.5610.340.279*FLU* Fluconazole, *VOR* Voriconazole, *ITR* Itraconazole

Discussion {#Sec12}
==========

To our knowledge, this is the first study to examine the shifting trends in bacteriology and antimicrobial resistance among GI fistula patients in China. Our findings indicate a significant increase in the percentage of IAIs attributable to Gram-negatives bacteria, with a corresponding decrease in the percentage attributable to Gram-positive isolates. There was a trend for increased resistance prevalence levels to certain antibiotics for Gram-negative bacteria, especially carbapenems.

*K. pneumonia* and *A. baumannii* have gained notoriety as important pathogens because of their increasing resistance to antibiotics and a rise in the number of severe infections caused by these micro-organisms in surgical settings \[[@CR16]\]. We found an increase in IAIs attributable to *K. pneumonia* and *A. baumannii* infection over time, although this increase did not reach statistical significance. Colonization with these bacteria have been described as the reason for high incidence in surgical wards and this could be prevented through effective infection control \[[@CR17], [@CR18]\]. Therefore, we must heighten our awareness of the importance of infection control.

ESBL production which can hydrolyze β-lactam antibiotics has been increasingly identified worldwide amongst the *Enterobacteriaceae* family, particularly *E. coli* and *K. pneumonia* \[[@CR19]\]. In the present study, the overall prevalence of ESBL-positive strains of *E. coli* was 63.9%, which decreased significantly over time, and the overall prevalence of ESBL-positive strains of *K. pneumonia* was 37.3%, which did not significant change over the study periods. These levels are somewhat lower than those reported by SMART research in 2012 and 2013 \[[@CR10]\]. Carbapenems and piperacillin-tazobactam are the most potent and reliable antibiotics for the treatment of ESBL-producing infection \[[@CR20]\]. In our study, we found that resistance to piperacillin-tazobactam decreased over time both ESBL-producing *E. coli* (*P* = 0.02) and *K. pneumonia* (*P* = 0.008). It suggests that piperacillin-tazobactam is a suitable treatment option for these infections \[[@CR21]\].

Resistance to carbapenems is associated with high mortality and has been an emerging concern worldwide \[[@CR22], [@CR23]\]. The overall prevalence of imipenem resistance in *E. coli* isolates was 20.6%, which significantly increased over time. Prevalence in *K. pneumonia* was 60.2%, which did not change over time. Both these prevalence levels are higher than previous reports \[[@CR9], [@CR24]--[@CR26]\]. This may be because the majority of our patients have transferred from other hospitals and have been treated with antibiotics for a number of days, which has been shown to be a risk factor for carbapenem resistance \[[@CR27]\]. High resistance prevalence has also resulted from its spread in surgical wards and ICUs \[[@CR12]\]. Standard infection control practice (basic hand hygiene, active surveillance cultures of patients, staff, and the environment) should be carried out to prevent the colonization and spread of resistant bacteria \[[@CR8], [@CR28], [@CR29]\].

The prevalence of multidrug resistance amongst *A. baumannii* isolates makes carbapenem the most effective treatment \[[@CR30]\]. Carbapenem resistance has become a serious problem, with prevalence reaching a remarkable 95.6% of all isolates in our study. Similarly high levels have been reported in blood stream infections \[[@CR23]\]. Once carbapenem resistant *A. baumannii* emerges, the infected patient has little chance of effective treatment \[[@CR31]\]. Therefore, we need to pay attention to source control and limiting the spread of carbapenem-resistant bacteria.

*P. aeruginosa* is another a common Gram-negative non-fermenting pathogen causing IAIs. In this study, the most efficient antimicrobial agent for *P. aeruginosa* was found to be amikacin, as has been reported elsewhere \[[@CR32]\]. However, we rarely treat patients with amikacin because of its renal toxicity. In our study we observed a significant decrease in resistance to piperacillin-tazobactam over time, suggesting that piperacillin- tazobactam could be the first choice treatment option for patients infected by *P. aeruginosa*, as recommended by several studies \[[@CR33], [@CR34]\].

The proportion of Gram-positive bacterial isolates that were *Enterococcus* increased over time. Antibiotic resistance rates for this group of pathogens also increased. *Staphylococcus* isolates had high levels of penicillin G, macrolide, and clindamycin resistance, but no resistance to vancomycin or linezolid was observed. Antibiotics resistance levels were lower among Gram-positive than Gram-negative bacteria. we therefore recommend focusing on Gram-negative bacteria with high antibiotic resistance in GI fistula patients.

In an attempt to identify factors that might influence antibiotic resistance emergence, we analyzed the clinical characteristics of patients. We found that patients in the second study period were older (aged \>65 years) and were more likely to suffer cancer, both of which have been demonstrated as risk factors for antibiotic resistance \[[@CR8], [@CR18], [@CR35]\]. We also found more IAIs caused by lower GI fistula in the second study period. A recent study by *Mu* et al. reported that antibiotic intervention exerts location-specific effects on antibiotic resistance genes (increased in the lower GI tract) \[[@CR36]\]. Most of our patients were transferred from other hospitals, which means they had been previously treated with antibiotics and were therefore at increased risk of antibiotic resistance. Excessive antibiotic use has been linked with the development of resistance, which is a common practice in many developing countries \[[@CR18]\]. Combined, these factors at least partly explain the increase in antibiotic resistance that we have observed. We found that smaller ICU patients showed higher antibiotic resistance. And that again underlines the serious antibiotic resistance.

Inappropriate use of antibiotics and inadequate source control were found to be independent predictors of mortality in a previous analysis \[[@CR37]\]. High levels of antibiotic resistance have left few treatment options available to surgeons \[[@CR8]\]. However, we found no change in mortality rates over time. This could partially be attributable to the effective management of source control. Newer IAI treatment guidelines recommend intravenous antimicrobial agents as a supplement to source control, and source control may be an available option for surgeons to prevent the emergence of antibiotic-resistant microbial strains \[[@CR38]\].

There are some limitations to our study. First, it is a retrospective and single-center surveillance study, which may explain the higher resistance levels observed in our study than other reports from China \[[@CR23]\]. However, the critically ill patients at our center were transferred from other hospitals throughout the country, so our study may represent the bacteriology and antimicrobial resistance profiles of severely infected GI fistula patients in China more generally. Second, we did not perform polymerase chain reaction (PCR) and DNA sequencing of isolates. Third, we did not use the unified CLSI breakpoints, as annually updated. In fact, our microbiology laboratory updated determinations according to the newest CLSI documents and 2008--2015 isolates were determined by each year's documents. Change of breakpoints might cause fluctuations of antimicrobial resistance in short-term surveillances \[[@CR12]\]. But there is not a large difference between CLSI breakpoints. And a longitudinal surveillance spanning over 8 years is of great significance for monitoring resistance, which may minimize referral bias.

Conclusions {#Sec13}
===========

This study illustrates the shifting trends in bacteriology and antimicrobial resistance in GI fistula patients in China over time. Gram-negative bacteria have become a more significant cause of IAIs in these patients. Currently, carbapenem resistances in Gram-negative bacteria is a serious problem in this patient group. Our findings confirm the urgent need to continue surveillance studies that monitor bacteriology and antimicrobial resistance trends. Infection control and source control are important tools for surgeons to use to prevent the emergence of isolated antibiotic-resistant pathogens.
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===============

Additional file 1: Table S1.Bacterial identification of isolates from intra-abdominal infections in a Tertiary-Care Hospital during 2008 and 2015. (DOCX 15 kb)
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